[{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : TWYMEEG (imeglimin hydrochloride), enhances insulin action by inhibiting hepatic glucose output and improving insulin signalling in both liver and skeletal muscle, in type 2 diabetes patients.

                          Brand Name : Twymeeg

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 07, 2024

                          Lead Product(s) : Imeglimin Hydrochloride

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Poxel

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Korlym (mifepristone) is an approved selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated in phase 4 for cushing syndrome.

                          Brand Name : Korlym

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 29, 2024

                          Lead Product(s) : Mifepristone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.

                          Brand Name : Korlym

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 15, 2024

                          Lead Product(s) : Mifepristone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Korlym (mifepristone) blocks cortisol receptors to manage hyperglycemia in adults with Cushing's syndrome who have type 2 diabetes or glucose intolerance.

                          Brand Name : Korlym

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 15, 2024

                          Lead Product(s) : Mifepristone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, which is investigated in combination with insulin degludec for the treatment of type 1 diabetes.

                          Brand Name : Afrezza

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 06, 2023

                          Lead Product(s) : Insulin Lispro

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Afrezza (human insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist and works as starts lowering blood sugars in ~12 minutes for adults living with type 1 or type 2 diabetes.

                          Brand Name : Afrezza

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 22, 2023

                          Lead Product(s) : Insulin Lispro

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : JATENZO (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions, for the treatment of adult hypogonadal men with chronic kid...

                          Brand Name : Jatenzo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 16, 2022

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank